Medical Equipment & Devices
FNArena Windows (Sectors)
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
Latest Stories
Tim Boreham highlights the significance of a new contract win for Pro Medicus and the company’s AI capacity
Oct 23 2023
FDA approval for Cyclopharm’s device-as-a-drug is welcome news, Tim Boreham reports
Oct 09 2023
| ASX CODE | COMPANY NAME | LAST PRICE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET |
|---|---|---|---|---|---|---|
| 4DX | 4DMEDICAL LIMITED | $0.96 | $1.27 | $0.29 |
$1.40 |
|
| CAT | CATAPULT GROUP INTERNATIONAL LIMITED | $1.27 | $1.35 | $0.61 |
$1.525 |
|
| CBL | CONTROL BIONICS LIMITED | $0.04 | $0.20 | $0.04 |
$0.09 |
|
| CGS | COGSTATE LIMITED | $1.42 | $2.46 | $1.14 |
$1.60 |
|
| COH | COCHLEAR LIMITED | $273.04 | $274.70 | $197.74 | 49.3 |
$236.90 |
| CU6 | COCHLEAR LIMITED | $1.43 | $xx.xx | $xx.xx | xx.x | xx.xx |
| CYC | CYCLOPHARM LIMITED | $2.06 | $xx.xx | $xx.xx | xx.x | xx.xx |
| EBR | EBR SYSTEMS INC | $0.60 | $xx.xx | $xx.xx | xx.x | xx.xx |
| FPH | FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED | $22.15 | $xx.xx | $xx.xx | xx.x | xx.xx |
| IDX | INTEGRAL DIAGNOSTICS LIMITED | $1.78 | $xx.xx | $xx.xx | xx.x | xx.xx |
| IME | IMEXHS LIMITED | $0.66 | $xx.xx | $xx.xx | xx.x | xx.xx |
| IPD | IMPEDIMED LIMITED | $0.14 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MX1 | MICRO-X LIMITED | $0.13 | $xx.xx | $xx.xx | xx.x | xx.xx |
| NAN | NANOSONICS LIMITED | $4.33 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PEB | PACIFIC EDGE LIMITED | $0.09 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PGC | PARAGON CARE LIMITED | $0.19 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PME | PRO MEDICUS LIMITED | $88.41 | $xx.xx | $xx.xx | xx.x | xx.xx |
| RMD | RESMED INC | $24.34 | $xx.xx | $xx.xx | xx.x | xx.xx |
| TRJ | TRAJAN GROUP HOLDINGS LIMITED | $1.27 | $xx.xx | $xx.xx | xx.x | xx.xx |
| VHT | VOLPARA HEALTH TECHNOLOGIES LIMITED | $0.80 | $xx.xx | $xx.xx | xx.x | xx.xx |
Previous Stories
Dr Boreham’s Crucible: Painchek
Sep 11 2023
Tim Boreham highlights a device used to detect pain in non-verbal patients, such as those suffering dementia and infants
Margins Signal Integral Diagnostics Recovery
Sep 07 2023
Analysts identify a second half FY23 inflection point for Integral Diagnostics
ResMed: Finding A Base?
Aug 15 2023
After a sharp pullback for ResMed, Michael Gable of Fairmont Equities suggests a base may soon be formed, providing a buying opportunity
August Turns ResMed Into Nigel NoMates
Aug 09 2023
A miss on the Q4 gross margin and Eli Lilly targeting the CPAP market have kept ResMed shares under selling pressure since Friday last week
Dr Boreham’s Crucible: Lumos Diagnostics
Jun 19 2023
Tim Boreham takes a look at Lumos Diagnostics, which specialises in rapid point-of-care tests to help healthcare professionals diagnose and manage medical conditions more accurately
Fisher & Paykel Healthcare: Lower Margin, Higher Spending
May 30 2023
Following FY23 results for Fisher & Paykel, brokers lowered earnings forecasts on a delayed margin recovery and future spending plans
Dr Boreham’s Crucible: Impedimed
May 08 2023
Tim Boreham reports a change in CEO has given cancer monitoring biotech Impedimed a new lease of life
Treasure Chest: ResMed’s Benevolent Monopoly
May 01 2023
FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. Today’s idea is ResMed
Dr Boreham’s Crucible: Volpara Health Technologies
Apr 26 2023
Volpara Health Technologies is revolutionising breast cancer detection. Tim Boreham investigates
Dr Boreham’s Crucible: SDI
Mar 16 2023
Tim Boreham gets his teeth into the opportunity ahead for listed dental products company SDI
